0.52%| Prev Close: | 52.35 |
|---|---|
| Open: | N/A |
| Bid: | 51.96 x 400 |
| Ask: | 52.00 x 500 |
| 1y Target Est: | 47.58 |
| Beta: | 0.55 |
| Next Earnings Date: | N/A |
| Day's Range: | N/A - N/A |
|---|---|
| 52wk Range: | 39.72 - 52.72 |
| Volume: | 0 |
| Avg Vol (3m): | 2,044,670 |
| Market Cap: | 65.44B |
| P/E (ttm): | 11.58 |
| EPS (ttm): | 4.52 |
| Div & Yield: | 3.80 (7.40%) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- [$$] Digest Data on Nektar-AstraZeneca's Naloxegolat Barrons.com(Wed, May 22)
- The 5 Highest-Paying Dividend Stocks in Big Pharmaat Motley Fool(Wed, May 22)
- AstraZeneca Reaches New 52-Week High (AZN)at TheStreet(Wed, May 22)
- Do Major Drug Manufacturers Have Room to Grow?at Motley Fool(Wed, May 22)
- Santarus Is a Real Gas!at Motley Fool(Wed, May 22)
- Par Pharmaceutical begins shipment of generic Atacandtheflyonthewall.com(Wed, May 22)
- The Top 3 Diseases Caused by Stressat Motley Fool(Tue, May 21)
- 3 Neil Woodford High-Yield Sharesat Motley Fool(Tue, May 21)
- AstraZeneca says Phase III studies of Naloxegol met primary, secondary endpointsat theflyonthewall.com(Tue, May 21)
- InPlay: AstraZeneca presents results of two pivotal Phase III studies of naloxegol showing the 25 mg dose of the investigational drug met its primary and secondary endpoints for efficacy and showed a safety profile consistent with previousBriefing.com(Tue, May 21)
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013Business Wire(Tue, May 21)
- AstraZeneca: A Dividend Payer With An Attractive Growth Prospectat Seeking Alpha(Mon, May 20)
- Statin Users May Have a Reason to Rejoice After This Dataat Motley Fool(Sun, May 19)
- Pick Your Poison: Overweight or High Cholesterolat Motley Fool(Sun, May 19)
- 1 Giant Leap for MannKindat Motley Fool(Sat, May 18)
Press Releases
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013Business Wire(Tue, May 21)
- Assessing Your Asthma is Key to Taking ControlPR Newswire(Mon, May 13)
- Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month PeriodBusiness Wire(Mon, May 6)
Reports
- ValuEngine Industry Report for Large CAP PharmaValuEngine, Inc.(May 22)
- Market Edge Equity Research ReportMarket Edge(May 20)
- AstraZeneca ADSS&P Capital IQ – STARS Reports(May 18)